See the DrugPatentWatch profile for Onivyde
Onivyde's molecular structure is that of irinotecan hydrochloride trihydrate [1]. It is a topoisomerase I inhibitor, meaning it works by blocking an enzyme that helps DNA repair itself in cancer cells [2]. This blockage leads to DNA damage and ultimately cell death [2]. The chemical name for irinotecan is (S)-4,11-diethyl-3,4,12,14-tetrahydro-4,11-dihydroxy-6-methoxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-9,13(15H,17H)-dione hydrochloride trihydrate [3].
What is Onivyde used to treat?
Onivyde is used in combination with other medications to treat pancreatic cancer [2]. Specifically, it is indicated for patients with metastatic pancreatic adenocarcinoma who have disease progression on or after a gemcitabine-based chemotherapy regimen [2].
How does Onivyde work in the body?
Onivyde is a prodrug of SN-38, which is the active cytotoxic metabolite [1]. After administration, Onivyde is hydrolyzed to SN-38 [1]. SN-38 then binds to the topoisomerase I-DNA complex, preventing the re-ligation of DNA breaks [2]. This results in DNA damage and apoptosis (programmed cell death) in cancer cells [2].
What is the difference between Onivyde and other chemotherapy drugs?
Onivyde is a liposomal formulation of irinotecan [4]. This means it is encapsulated in tiny fat bubbles (liposomes) which can affect how the drug is distributed in the body [4]. This liposomal formulation is designed to deliver SN-38 to tumor tissues more effectively and prolong its presence, potentially leading to improved efficacy and a different side effect profile compared to non-liposomal irinotecan [4].
When does the patent for Onivyde expire?
Patent information for Onivyde is complex and can involve multiple patents covering different aspects of the drug, such as its formulation, method of use, and manufacturing [5]. DrugPatentWatch.com provides a database for tracking patent expirations and exclusivity periods for pharmaceuticals [5]. Specific patent expiry dates for Onivyde would need to be consulted through such a service.
What are the potential side effects of Onivyde?
Common side effects of Onivyde can include diarrhea, nausea, vomiting, low white blood cell count, fatigue, decreased appetite, and abdominal pain [2]. The liposomal formulation may influence the incidence and severity of certain side effects [4].
What are the risks associated with Onivyde treatment?
Serious risks associated with Onivyde include severe diarrhea, which can be life-threatening and requires prompt medical attention [2]. Other risks include bone marrow suppression, leading to low blood cell counts, and hypersensitivity reactions [2].
Can Onivyde be used in combination with other treatments?
Onivyde is approved for use in combination with other chemotherapy agents, such as leucovorin and fluorouracil, for the treatment of metastatic pancreatic cancer [2].
What is the pricing for Onivyde?
Pricing for Onivyde can vary depending on factors such as insurance coverage, pharmacy, and geographic location. For specific pricing information, individuals should consult with their healthcare provider or pharmacist [2].
Are there any approved generic or biosimilar versions of Onivyde?
As of current information, Onivyde is a branded drug. The development of generic versions of complex drug formulations like liposomal irinotecan can be challenging and may depend on patent protections and regulatory pathways [5].
Sources:
[1] https://www.drugpatentwatch.com/drug/onivyde
[2] https://www.onivyde.com/
[3] https://pubchem.ncbi.nlm.nih.gov/compound/Irinotecan-hydrochloride-trihydrate
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5790322/
[5] https://www.drugpatentwatch.com/